Is my wrist suitable for ChondroFiller injection?

Wrist cartilage damage — whether from a distal radius fracture, a longstanding scaphoid injury, or degenerative joint disease — is a recognised indication for ChondroFiller injection. The treatment involves an ultrasound-guided outpatient injection of a collagen scaffold that gels inside the joint and supports the body's own repair processes; it is not a surgical or arthroscopic procedure.

One assumption worth addressing early: there is no upper age limit on the injection pathway, and the degree of cartilage loss does not automatically disqualify a patient. Even where a wrist shows advanced surface damage, an injection pathway may still be clinically appropriate depending on four dimensions that shape the assessment — the joint mechanics (physics), the tissue environment (chemistry), the patient's biological repair capacity (biology), and how long the damage has been present (timing). These four lenses map onto a structured suitability assessment that routes patients toward one of three options: injection alone, injection combined with a complementary therapy, or a different pathway entirely. The self-assessment tool is a starting point, not a clinical verdict.

Final suitability is determined at a formal consultation, which includes imaging review, joint mechanics assessment, and discussion of individual treatment goals. ChondroFiller injection for wrist cartilage damage is delivered as an ultrasound-guided outpatient appointment at the London Cartilage Clinic on Harley Street.

Understanding why the scaffold works — and how it differs from simpler joint injections — depends on the mechanism behind that gel.

How ChondroFiller injection works in a wrist joint

ChondroFiller is a CE-marked Class III medical device — an acellular Type I collagen hydrogel that arrives at the joint in liquid form. Under ultrasound guidance, it is introduced into the cartilage defect as an outpatient injection, where it gels in situ within three to five minutes, conforming to the contours of the damage rather than requiring any cutting or theatre preparation.

Once set, the scaffold functions through a process called acellular matrix-induced chondrogenesis. Rather than delivering cells from an external source, it provides a three-dimensional framework that recruits the patient's own progenitor cells — drawn from the surrounding synovium and the subchondral bone beneath the defect — and supports the body's own repair processes. The word 'acellular' is important: no cell harvest, no donor tissue, no second procedure.

The wrist's constrained anatomy turns out to suit this approach well. Published research in wrist cartilage reconstruction found that defects in this joint typically required only 0.2–0.3 mL of the 1 mL preparation per defect — a small, precise volume that fits the tight spaces of wrist anatomy without overflow into surrounding structures. That same research noted that flush application (neither underfilling nor overfilling) was the technically critical factor; the precision that ultrasound guidance affords is therefore meaningful here, not incidental.

How this single-stage collagen scaffold compares with other available options — including joint lubricants and surgical cell-transplantation techniques — is covered in the next section.

What the clinical evidence shows for wrist cartilage

The clearest direct evidence comes from a 2025 prospective study by Demmer et al., which enrolled 59 patients with intra-articular distal radius fractures and applied ChondroFiller to 25 wrists — delivered arthroscopically as part of a controlled research protocol rather than as an outpatient injection. Follow-up arthroscopy showed significantly better cartilage quality scores in treated wrists than in controls: median Outerbridge score 1.5 versus 3 (P=0.006) and ICRS score 1 versus 3 (P=0.002). No additional complications occurred in the treated group. This remains the only published study examining ChondroFiller specifically in the wrist joint — the evidence base is prospective and controlled, but also early-stage, and not yet confirmed by a randomised trial.

Supporting evidence comes from adjacent small-joint research. Corain et al. (2023) studied 43 patients with trapeziometacarpal (thumb-base) osteoarthritis spanning all Eaton-Littler stages, each receiving a single ChondroFiller infiltration. Both early- and advanced-stage groups achieved significant reductions in NRS pain scores and DASH questionnaire results at 30 days and six months. MRI confirmed structural changes — reduced bone marrow oedema, diminished periarticular effusion, and measurable widening of the joint space — alongside increases in grip and pincer strength on Jamar and pinch tests. The constrained anatomy of the thumb-base joint makes these findings relevant supporting context, though they do not map directly onto post-traumatic distal radius cartilage defects.

Across the broader published evidence base — spanning knee, hip, and small-joint applications — 70–85% of patients achieve meaningful symptom relief at three to five years, with a reported complication rate of approximately 0%.

Four gaps in the current evidence base are clear: a single prospective wrist study, no randomised controlled trial in the wrist, no long-term wrist-specific follow-up data, and no published ChondroFiller data specific to TFCC-related cartilage damage. The existing findings are consistent and encouraging; these limits define what they can and cannot yet confirm.

How ChondroFiller injection compares to other wrist treatments

Patients researching wrist cartilage options typically encounter a short list of alternatives before arriving at ChondroFiller injection, and the differences between them are meaningful rather than cosmetic.

Hyaluronic acid (HA) viscosupplementation works by lubricating the joint and may reduce pain temporarily in some patients, but it does not repair cartilage structure. The mechanism — coating joint surfaces rather than filling a defect — means HA and ChondroFiller injection are addressing different problems. For patients who have already received HA without adequate benefit, a ChondroFiller assessment is reasonable precisely because the two treatments operate through distinct pathways.

Microfracture is an arthroscopic surgical procedure that penetrates the subchondral bone to stimulate a clot that matures into fibrocartilage — scar-like tissue rather than the hyaline-like repair that ChondroFiller injection is designed to support. Published data place reoperation rates for microfracture at up to 41%, compared with approximately 3–8% for ChondroFiller across its broader evidence base. These figures come from different joint populations and patient profiles, so direct wrist-specific comparison is not possible from current evidence; the structural difference in repair tissue quality is, however, a consistent finding.

ACI and MACI (autologous cell implantation techniques) require a two-stage surgical process: an initial procedure to harvest the patient's own cartilage cells, laboratory expansion, and a second theatre procedure for implantation. ChondroFiller injection is single-stage and takes place in an outpatient setting under ultrasound guidance.

A distinction that sometimes causes confusion: Arthrosamid (a polyacrylamide hydrogel) is a permanent, non-regenerative joint filler — it cushions the joint but does not provide a scaffold for repair. ChondroFiller injection is a temporary regenerative scaffold that supports the body's own repair processes through matrix-induced chondrogenesis. The two products have different mechanisms and serve different clinical roles.

How the clinic assessment routes wrist patients

Routing a wrist patient toward the right treatment begins before any consultation. The eight-question self-assessment at London Cartilage Clinic works across four clinical lenses, each capturing a distinct aspect of joint readiness:

• Physics — how the joint loads and whether alignment places uneven stress on the damaged surface
• Chemistry — the degree of inflammatory activity in the joint environment
• Biology — the patient's underlying repair potential, including bone health and tissue healing history
• Timing — how long the cartilage damage has been present and whether the window for scaffold-supported repair is still open

The output maps to one of three pathway tiers. Most wrist patients qualify for ChondroFiller injection alone — a single outpatient appointment under ultrasound guidance. Where the joint environment scores more adversely on the chemistry lens, a combined ChondroFiller and Arthrosamid injection (guide cost £6,000) addresses both regeneration and the mechanical joint milieu simultaneously. For the most advanced cases, ChondroFiller combined with Arthrosamid and MSC therapy (guide cost £11,000) brings additional biological support. The tiers are clinical, not demographic: no upper age limit and no defect-size exclusion applies at the injection pathway level.

The self-assessment is a routing tool rather than a clinical verdict. Formal consultation and imaging are required before any pathway is confirmed — joint mechanics, scan findings, and treatment goals all inform the final recommendation.

Once a pathway is agreed and the injection given, most patients notice localised swelling peaking at around 24 hours, a dull pressure-like discomfort, and some stiffness — all of which typically settle within 48–72 hours without hospitalisation. The signs that warrant prompt clinic contact are distinct from this expected scaffold response: increasing joint warmth, spreading redness, swelling that worsens rather than improves after 48 hours, or the onset of fever.

Cost, access, and booking in London

ChondroFiller injection is not NHS-funded and sits outside standard Bupa and AXA cover; treatment is self-funded, though the clinic can provide an itemised invoice for submission to independent insurers.

Guide pricing at London Cartilage Clinic — all-inclusive (consultation, ultrasound guidance, the injectable scaffold, intravenous antibiotic cover, and a six-week follow-up) — runs from £3,000 for one box to £5,500 for two and £8,000 for three. Most wrist cartilage defects are managed within a single box. For those who have already reviewed the combination pathways described in the preceding section, the combined ChondroFiller and Arthrosamid guide cost is £6,000; ChondroFiller, Arthrosamid, and MSC therapy together carries a guide cost of £11,000. Confirm all figures with the clinic at consultation, as individual presentations vary. Patients considering treatment at mainland European centres — primarily Germany and Austria — typically find comparable pricing in the range of €2,500–€4,500.

The appointment itself takes approximately 30–45 minutes as an outpatient procedure; no theatre admission or overnight stay is involved.

Professor Paul Y.F. Lee, who leads the programme at the London Cartilage Clinic on Harley Street, is the UK's principal clinician delivering ChondroFiller injection — a consideration worth weighing alongside geography and cost when assessing options. For patients who have worked through the clinical evidence and their own self-assessment, the practical next step is a formal consultation where imaging and joint mechanics can be reviewed against an individual treatment goal.

Liquid Cartilage™ is delivered in the UK at the London Cartilage Clinic on Harley Street. Book a wrist cartilage assessment at londoncartilage.com.